Challenges and Opportunities for Osteoporosis Care During the COVID-19 Pandemic
Open Access
- 3 August 2021
- journal article
- review article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (12), e4795-e4808
- https://doi.org/10.1210/clinem/dgab570
Abstract
Purpose The coronavirus disease 2019 (COVID-19) has both directly and indirectly affected osteoporosis diagnosis and treatment throughout the world. Methods This mini-review summarizes the available evidence regarding the effects of COVID-19, its treatment, and the consequences of the pandemic itself on bone health. Additionally, we review evidence and expert recommendations regarding putative effects of osteoporosis medications on COVID-19 outcomes and vaccine efficacy and summarize recommendations for continuation of osteoporosis treatment during the pandemic. Results The use of standard screening procedures to assess for osteoporosis and fracture risk declined dramatically early in the pandemic, while rates of fragility fractures were largely unchanged. COVID-19, its treatments, and public health measures to prevent viral spread are each likely to negatively affect bone health. Osteoporosis treatments are not known to increase risk of adverse events from COVID-19, and preclinical data suggest possible beneficial effects of some therapies. Vitamin D deficiency is clearly associated with adverse outcomes from COVID-19, but it remains unclear whether vitamin D supplementation may improve outcomes. Osteoporosis treatment should be continued whenever possible, and recommendations for substituting therapies, if required, are available. Conclusion The COVID-19 pandemic has decreased screening and disrupted treatment for osteoporosis. Osteoporosis medications are safe and effective during the pandemic and should be continued whenever possible. Further studies are needed to fully understand the impact of the COVID-19 pandemic on long-term bone health.Keywords
Funding Information
- National Institutes of Health Ruth L. Kirschstein Institutional National Research Service (T32DK007028)
This publication has 174 references indexed in Scilit:
- Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2013
- Serum 1,25-Dihydroxyvitamin D: An Outcome Prognosticator in Human SepsisPLOS ONE, 2013
- Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37PLOS ONE, 2011
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Osteoporosis International, 2011
- Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill*Critical Care Medicine, 2011
- Weight Loss, Exercise, or Both and Physical Function in Obese Older AdultsThe New England Journal of Medicine, 2011
- Vitamin D and the intracrinology of innate immunityMolecular and Cellular Endocrinology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with OsteoporosisJournal of Clinical Endocrinology & Metabolism, 2009
- Population-Based Fracture Risk Assessment and Osteoporosis Treatment Disparities by Race and GenderJournal of General Internal Medicine, 2009